News

Looking Beyond BTK Inhibitors and Venetoclax for Double-Refractory CLL

Relapsed or Refractory MCL: Brexucabtagene Autoleucel vs Allogeneic Transplant

Has Access to Multiple Agents Improved Survival in Older Patients With Mantle Cell Lymphoma?

Venetoclax/Obinutuzumab May Improve PFS in CLL

Mantle Cell Lymphoma: Comparing Outcomes With Time-Limited Initial Regimens

Factors Impacting Overall Survival Among Patients With CLL on Targeted Therapy

Early Results With Single-Agent Epcoritamab in Resistant CLL

Relapsed Mantle Cell Lymphoma: Treatment Strategies After CAR T-Cell Therapy

Early Research Findings on the Use of Zanubrutinib Plus Sonrotoclax in CLL

Long-Term Outcomes With Induction Therapies for Mantle Cell Lymphoma

Updates From TRANSCEND CLL 004: Use of Lisocabtagene Maraleucel in CLL or SLL

AMPLIFY Trial Investigates Triplet Immunotherapy vs Chemoimmunotherapy in CLL

OASIS II: Triplet Immunotherapy Regimen for Treatment-Naive MCL

Combining Acalabrutinib and Rituximab in Older Patients With Mantle Cell Lymphoma

BRUIN CLL-321 Trial: Update on Pirtobrutinib for BTK Inhibitor–Pretreated CLL or SLL

Combination of Lisocabtagene Maraleucel and Ibrutinib in Aggressive CLL or SLL

Activity of Novel Antibody-Drug Conjugate in Resistant Mantle Cell Lymphoma

Acalabrutinib-Based Combination Under Study in Previously Untreated CLL

Diagnostic and Insurance Disparities Among Minority Patients With Lymphoma

European Study on Chemoimmunotherapy vs BTK Inhibitors in CLL

Use of ASCT in Patients With Mantle Cell Carcinoma in Complete Remission

NCCN Announces Grants Awarded to Quality Improvement Research Projects in CLL/SLL

Can Venetoclax Boost Response to CAR T-Cell Therapy in CLL?

New Standard of Care for Older Patients With Mantle Cell Lymphoma?

Long-Term Outcomes of CAR T-Cell Therapy in Responders With CLL

Novel BTK Inhibitor–Based Combination First-Line Treatment of CLL

Triplet Regimen Under Study in Untreated CLL

Impact of Immunosenescence on CAR T-Cell Treatment in CLL

ZUMA-2 Trial Supports Brexucabtagene Autoleucel in BTK Inhibitor–Naive Relapsed or Refractory MCL

Adding BTK Inhibitor to Chemoimmunotherapy in Mantle Cell Lymphoma

Factors Influencing CAR T-Cell Therapy Outcomes in Recurrent Mantle Cell Lymphoma

Is ASCT Necessary After Ibrutinib Treatment in Mantle Cell Lymphoma?

Acalabrutinib Combination Therapy Approved by FDA for Previously Untreated MCL